Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) announced the appointment of Mr. Sunil Kumar Singh as Senior Management Personnel, effective January 19, 2026. The Board of Directors approved this appointment based on the recommendations of the Nomination and Remuneration Committee, through a circular resolution passed on January 19, 2026. Mr. Sunil Kumar Singh joined Cohance Lifesciences in December 2025 as Chief Quality Officer. He brings over 35 years of extensive leadership experience in pharmaceutical quality across various segments including APIs, formulations, CDMO, and external manufacturing. Previously, he served as Global Head – Quality for the PSAI Business at Dr. Reddy’s Laboratories, with an additional enterprise-wide mandate as Global Head – Internal Audit & Compliance. His expertise includes building quality organizations, enhancing regulatory trust, and driving business growth through quality transformation, digitalization, and risk governance. He has a proven ability to deliver results and has worked with prominent pharmaceutical companies such as Mylan, Zydus, Glenmark, and Cipla. Mr. Sunil holds a Master’s degree in Management and a B.Sc. (Tech) in Pharmaceuticals and Fine Chemicals.
